PriceTargets.com logo

Silk Road Medical - SILK Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $27.50
  • Forecasted Upside: 0.04%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$27.49 As of 09/17/2024 01:00 AM ET
+0 (0.00%)
Get New Silk Road Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SILK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SILK

Analyst Price Target is $27.50
▲ +0.04% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Silk Road Medical in the last 3 months. The average price target is $27.50, with a high forecast of $27.50 and a low forecast of $27.50. The average price target represents a 0.04% upside from the last price of $27.49.

This chart shows the closing price for SILK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 2 investment analysts is to reduce stock in Silk Road Medical. This rating has held steady since June 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 2 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 2 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 2 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 2 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
12/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
3/20/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
5/19/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
6/18/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/17/2024Stifel NicolausReiterated RatingBuy ➝ Hold$23.00 ➝ $27.50
7/11/2024ArgusDowngradeBuy ➝ Sell
6/18/2024Lake Street CapitalReiterated RatingBuy ➝ Hold$28.00 ➝ $27.50
5/1/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$19.00 ➝ $21.00
5/1/2024Piper SandlerBoost TargetNeutral ➝ Neutral$18.00 ➝ $20.00
3/7/2024ArgusUpgradeHold ➝ Buy$24.00
2/29/2024Stifel NicolausBoost TargetBuy ➝ Buy$20.00 ➝ $23.00
2/29/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$10.00 ➝ $19.00
2/29/2024Piper SandlerBoost TargetNeutral ➝ Neutral$11.00 ➝ $18.00
1/19/2024Stifel NicolausUpgradeHold ➝ Buy$9.00 ➝ $20.00
1/3/2024Lake Street CapitalInitiated CoverageBuy$20.00
10/24/2023Wolfe ResearchUpgradeUnderperform ➝ Peer Perform
10/11/2023Piper SandlerLower TargetNeutral ➝ Neutral$25.00 ➝ $11.00
10/11/2023CL KingDowngradeBuy ➝ Neutral
10/11/2023CitigroupDowngradeBuy ➝ Sell$35.00 ➝ $8.00
10/11/2023B. RileyDowngradeBuy ➝ Neutral$54.00 ➝ $14.00
10/11/2023Stifel NicolausDowngradeBuy ➝ Hold$45.00 ➝ $12.00
9/21/2023ArgusDowngradeBuy ➝ Hold
9/5/2023OppenheimerInitiated CoverageOutperform$30.00
8/14/2023CitigroupLower TargetBuy ➝ Buy$48.00 ➝ $35.00
8/2/2023B. RileyLower TargetBuy ➝ Buy$58.00 ➝ $54.00
8/2/2023Stifel NicolausLower TargetBuy ➝ Buy$50.00 ➝ $45.00
7/18/2023Wolfe ResearchLower Target$27.00 ➝ $13.00
7/12/2023Bank of AmericaDowngradeBuy ➝ Underperform$51.00 ➝ $28.00
7/12/2023JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$50.00 ➝ $28.00
5/23/2023CL KingInitiated CoverageBuy$47.00
5/22/2023ArgusLower Target$70.00 ➝ $55.00
5/15/2023Wolfe ResearchDowngradePeer Perform ➝ Underperform$27.00
5/10/2023Stifel NicolausLower Target$60.00 ➝ $50.00
5/10/2023Piper SandlerLower Target$46.00 ➝ $41.00
5/10/2023CitigroupLower Target$50.00 ➝ $48.00
4/3/2023CitigroupUpgradeNeutral ➝ Buy$50.00
3/31/2023B. RileyInitiated CoverageBuy$58.00
3/10/2023CitigroupUpgradeSell ➝ Neutral$50.00
2/7/2023Wolfe ResearchDowngradeOutperform ➝ Peer Perform
1/9/2023ArgusBoost Target$60.00 ➝ $70.00
11/22/2022Bank of AmericaInitiated CoverageBuy$60.00
11/15/2022CitigroupBoost Target$38.00
10/5/2022CitigroupBoost Target$33.00 ➝ $34.00
7/18/2022Stifel NicolausLower Target$55.00 ➝ $46.00
7/11/2022CitigroupDowngradeNeutral ➝ Sell$33.00
5/17/2022CitigroupLower Target$44.00 ➝ $33.00
4/5/2022Wolfe ResearchInitiated CoverageOutperform$48.00
4/4/2022Piper SandlerBoost TargetNeutral$38.00 ➝ $43.00
2/25/2022CitigroupLower TargetNeutral$45.00 ➝ $37.00
2/25/2022Piper SandlerLower Target$48.00 ➝ $38.00
1/3/2022Piper SandlerLower Target$55.00 ➝ $48.00
11/22/2021ArgusLower TargetBuy$70.00 ➝ $60.00
11/19/2021CitigroupUpgradeSell ➝ Neutral$50.00
11/10/2021Leerink PartnersLower TargetOutperform$75.00 ➝ $66.00
10/1/2021CitigroupDowngradeNeutral ➝ Sell$50.00
7/30/2021Piper SandlerLower TargetNeutral$58.00 ➝ $55.00
7/20/2021Leerink PartnersReiterated RatingOutperform
3/2/2021CitigroupLower Target$64.00 ➝ $59.00
11/11/2020Piper SandlerBoost TargetNeutral$54.00 ➝ $58.00
10/12/2020Leerink PartnersBoost TargetOutperform$60.00 ➝ $75.00
10/1/2020CitigroupDowngradeBuy ➝ Neutral$58.00 ➝ $71.00
8/21/2020Piper SandlerInitiated CoverageNeutral$54.00
8/6/2020Stifel NicolausBoost TargetBuy$47.00 ➝ $55.00
8/6/2020Leerink PartnersBoost TargetOutperform$51.00 ➝ $60.00
8/6/2020CitigroupBoost TargetBuy$50.00 ➝ $58.00
7/9/2020Leerink PartnersInitiated CoverageOutperform$51.00
7/1/2020Stifel NicolausReiterated RatingBuy$47.00
(Data available from 6/18/2020 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2025
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Silk Road Medical logo
Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
Read More

Today's Range

Now: $27.49
Low: $27.49
High: $27.49

50 Day Range

MA: $27.31
Low: $27.01
High: $27.50

52 Week Range

Now: $27.49
Low: $6.08
High: $27.51

Volume

N/A

Average Volume

1,200,763 shs

Market Capitalization

$1.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Silk Road Medical?

The following sell-side analysts have issued research reports on Silk Road Medical in the last year: Argus, Lake Street Capital, and Stifel Nicolaus.
View the latest analyst ratings for SILK.

What is the current price target for Silk Road Medical?

0 Wall Street analysts have set twelve-month price targets for Silk Road Medical in the last year. Their average twelve-month price target is $27.50, suggesting a possible upside of 0.0%. Stifel Nicolaus has the highest price target set, predicting SILK will reach $27.50 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $27.50 for Silk Road Medical in the next year.
View the latest price targets for SILK.

What is the current consensus analyst rating for Silk Road Medical?

Silk Road Medical currently has 1 sell rating and 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for SILK.

What other companies compete with Silk Road Medical?

Other companies that are similar to Silk Road Medical include Bausch + Lomb, Soleno Therapeutics, Inspire Medical Systems, PROCEPT BioRobotics and Envista. Learn More about companies similar to Silk Road Medical.

How do I contact Silk Road Medical's investor relations team?

Silk Road Medical's physical mailing address is 1213 INNSBRUCK DR., SUNNYVALE CA, 94089. The company's listed phone number is (408) 720-9002 and its investor relations email address is [email protected]. The official website for Silk Road Medical is www.silkroadmed.com. Learn More about contacing Silk Road Medical investor relations.